Table 5.
Comparison of Visual Outcomes in Patients Treated with Laser plus Ranibizumab versus Ranibizumab Alone
| Outcome | Branch Retinal Vein Occlusion |
Central Retinal Vein Occlusion |
||||
|---|---|---|---|---|---|---|
| Ranibizumab + Laser | Ranibizumab Alone | P Value | Ranibizumab + Laser | Ranibizumab Alone | P Value | |
| Week 48 completers | ||||||
| Mean BCVA (letter score) | (n = 20) | (n = 18) | (n = 18) | (n = 19) | ||
| Week 24 | 69.9 ± 3.1 | 61.3 ± 3.0 | 0.06 | 63.1 ± 3.3 | 62.8 ± 4.5 | 0.87 |
| Week 48 | 62.4 ± 2.7 | 64.1 ± 3.4 | 0.70 | 59.8 ± 4.1 | 62.8 ± 4.7 | 0.31 |
| Change from baseline to week 48 | −7.5 ± 1.9 | 2.8 ± 2.1 | <0.001 | −3.3 ± 2.7 | 0.0 ± 2.0 | 0.34 |
| Week 96 completers | ||||||
| Mean BCVA (letter score) | (n = 17) | (n = 18) | (n = 16) | (n = 17) | ||
| Week 24 | 73.0 ± 2.9 | 61.3 ± 3.0 | 0.01 | 63.1 ± 3.4 | 60.8 ± 4.8 | 0.71 |
| Week 96 | 71.0 ± 2.9 | 66.1 ± 2.8 | 0.24 | 63.8 ± 3.7 | 59.2 ± 5.0 | 0.89 |
| Change from baseline to week 96 | −2.0 ± 1.9 | 4.8 ± 2.8 | 0.03 | 0.69 ± 3.1 | −1.6 ± 3.1 | 0.60 |
| Week 144 completers | ||||||
| Mean BCVA (letter score) | (n = 17) | (n = 16) | (n = 15) | (n = 15) | ||
| Week 24 | 73.0 ± 2.9 | 61.0 ± 3.3 | 0.01 | 62.5 ± 3.6 | 61.7 ± 5.3 | 0.90 |
| Week 144 | 70.4 ± 2.9 | 64.1 ± 3.9 | 0.21 | 62.9 ± 4.3 | 55.1 ± 6.5 | 0.69 |
| Change from baseline to week 144 | −2.6 ± 2.2 | 3.1 ± 3.3 | 0.19 | 0.4 ± 4.3 | −6.7 ± 3.7 | 0.22 |
BCVA = best-corrected visual acuity.